Receptor-mediated targeting of 67Ga-deferoxamine-folate to folate- receptor-positive human KB tumor xenografts

Nuclear Medicine and Biology

Volumn 26, Issue 1, 1999, Pages 23-25

  Mathias, Carla J ^a   Wang, Susan ^b   Low, Philip S ^b   Waters, David J ^c   Green, Mark A ^a  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

67Ga Deferoxamine folate; Folate receptor; Tumor targeting

Indexed keywords

DEFEROXAMINE; FOLIC ACID; GALLIUM 67;

ANIMAL EXPERIMENT; ARTICLE; CANCER TRANSPLANTATION; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG UPTAKE; HUMAN; HUMAN CELL; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; NUDE MOUSE; TARGET ORGAN;

ANIMALS; CARRIER PROTEINS; DEFEROXAMINE; DOSE-RESPONSE RELATIONSHIP, RADIATION; FOLIC ACID; GALLIUM RADIOISOTOPES; HUMANS; ISOTOPE LABELING; KB CELLS; MALE; MICE; MICE, NUDE; RADIOPHARMACEUTICALS; RECEPTORS, CELL SURFACE; TISSUE DISTRIBUTION; TUMOR MARKERS, BIOLOGICAL;

EID: 0032892065     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(98)00076-6     Document Type: Article

References (13)

1. Antony A.C. The biological chemistry of folate receptors. Blood. 79:1992;2807-2820.
2. Campbell I.G., Jones T.A., Foulkes W.D. Folate-binding protein is a marker for ovarian cancer. Cancer Res. 51:1991;5329-5338.
3. Crom W. R. and Evans W. E. (1992) Methotrexate. In: Applied Pharmacokinetics, 3rd edn (Edited by Evans W. E., Schentag J. J., Jusko W. J. and Relling M. V.), pp. 29-1-29-42. Applied Therapeutics, Vancouver, WA.
4. Garin-Chesa P., Campbell I., Saigo P.E. Trophoblast and ovarian cancer antigen LK26, Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am. J. Pathol. 142:1993;557-567.
5. Hjelle J.T., Christensen E.I., Carone F.A., Selhub J. Cell fractionation and electron microscope studies of kidney folate-binding protein. Am. J. Physiol. 260:1991;C338-C346.
6. Mathias C.J., Lee R.J., Wang S., Waters D.J., Low P.S., Green M.A. Tumor-selective radiopharmaceutical targeting via receptor mediated endocytosis, evaluation of a gallium-67 labeled folate-deferoxamine conjugate [Abstract]. J. Nucl. Med. 36:1995;68P.
7. Mathias C.J., Wang S., Lee R.J., Waters D.J., Low P.S., Green M.A. Tumor selective radiopharmaceutical targeting via receptor mediated endocytosis of gallium-67-deferoxamine-folate. J. Nucl. Med. 37:1996;1003-1008.
8. Mathias C.J., Wang S., Waters D.J., Low P.S., Green M.A. Ga-67 and In-111 labeled folate-chelate conjugates for targeting tumor-associated folate binding protein (FBP) [Abstract]. J. Nucl. Med. 37:1996;347P-348P.
9. Mathias C.J., Wang S., Waters D.J., Turek J.J., Low P.S., Green M.A. Indium-111-DTPA folate as a radiopharmaceutical for targeting tumor-associated folate binding protein (FBP) [Abstract]. J. Nucl. Med. 38:1997;133P-134P.
10. 111In-DTPA-Folate as a potential folate-receptor-targeted radiopharmaceutical. J. Nucl. Med. 39:1998;1579-1585.
11. Mathias C.J., Waters D.J., Wang S., Low P.S., Green M.A. Indium-111 labeled indium(III)-DTPA-folate as a radiopharmaceutical for targeting tumor-associated folate receptors, the effect of tumor size on targeting selectivity and radiochemical analysis of excreted tracer. J. Labelled Compnd. Radiopharmaceut. 40:1997;365-367.
12. 67Ga-deferoxamine-folate, a potential radiopharmaceutical for tumor imaging. Bioconjugate Chem. 7:1996;56-62.
13. 111In-DTPA-Folate for use as a tumor-targeted radiopharmaceutical. Bioconjugate Chem. 8:1997;673-679.